Gencor, a global ingredients supplier, recently announced positive findings from a recent pharmacokinetic study examining the availability of its resveratrol ingredient, VeriSperse. The single-dose, double-blind, randomized study compared the pharmacokinetics of a standard commercially available resveratrol with VeriSperse, which contains a delivery technology called LipiSperse. The study was funded by Pharmako Biotechnologies.
 
Healthy adults were randomly selected to receive one of three single doses of resveratrol. One group received a dose of 75 mg of VeriSperse while another group received 150 mg of VeriSperse. The last group received a dose of 150 mg resveratrol without the LipiSperse delivery complex. The 150 mg dose of VeriSperse showed a 2-fold increase in absorption, and a 3-fold increase in Cmax of trans-resveratrol conjugates compared to the 150 mg Veri-te dose, thereby supporting LipiSperse as an effective mechanism in improving the absorption of resveratrol. The study showed no statistical difference between the 75 mg dose of VeriSperse to the 150 mg dose of standard resveratrol for AUC or Cmax of resveratrol conjugates.
 
“Like other polyphenols, the oral intake of resveratrol has a relatively low bioavailability,” Chase Shyroc, vice president of Sales and Business Development for Gencor, said. “By using the LipiSperse delivery system, we’ve seen significant increase in VeriSperse’s bioavailability and efficacy along with the benefit of improved functionality.”
 
A common challenge with the introduction of lipophilic active ingredients can often result in decreased active load in final formulations, Gencor said. However, LipiSperse increases the wettability of the crystal by lowering the surface tension enabling the dispersion of particles effectively in water and preventing the agglomeration of the crystals.